Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,032
datasets available to search
ShareScore release 0.9.0
Dataset results
2,032 results for “metastases”
Dataset related to article "Effect of chemotherapy on tumour-vessel relationship in colorectal liver metastases"
<p>This record contains raw data related to article “Effect of chemotherapy on tumour-vessel relationship in colorectal liver metastases"</p> <p><sup>Abstract</sup></p> <p>Chemotherapy is the fundamental companion of surgery for treatment of patients with colorectal liver metastases (CLMs)1 .<br> When chemotherapy leads to tumour shrinkage, this is expected to have two major effects. It reduces tumour burden and, most relevant for surgeons, shrinkage may detach CLMs from vessels, enabling more conservative procedures and increasing resectabil- ity. Although the first effect is indisputable, the second one has not been confirmed completely by data. In two studies 6,7 with some limitations, including small sample size and low adoption of targeted therapies, tumour shrinkage led to regression of tumour–vessel contact in only one-fifth of patients. The authors’ group has pursued an aggressive ultrasound- guided parenchyma-sparing approach based on a vessel-sparing policy, scheduling tumour detachment from vessels or partial<br> vein resection/reconstruction whenever possible since 2004. This has allowed accurate analysis of modification of the tumour–vessel relationship after chemotherapy. The aim of this study was to elucidate whether tumour shrinkage by chemother- apy corresponds to regression of CLM–vessel contact</p> <p> </p> <p> </p>
Dataset related to article "The Histopathological Growth Pattern of Colorectal Liver Metastases Impacts Local Recurrence Risk and the Adequate Width of the Surgical Margin"
<p>This record contains raw data related to article "The Histopathological Growth Pattern of Colorectal Liver Metastases Impacts Local Recurrence Risk and the Adequate Width of the Surgical Margin"</p> <p>Abstract</p> <p><strong>Background: </strong> The histopathological growth pattern (HGP) of colorectal liver metastases (CLM) has been associated with prognosis. This study was designed to elucidate if the HGP is associated with local recurrence risk and impacts the adequate width of surgical margin.</p> <p><strong>Methods: </strong> All consecutive patients resected for CLM in 2018-2019 were considered. HGP was prospectively classified as follows: desmoplastic, pushing, and replacement. Surgical margin was classified as follows: R0 (margin ≥ 1 mm), R1vasc (0-mm margin, tumor detachment from intrahepatic vessels), and R1par (tumor exposure along transection plane). R0 resections were further distinguished in R0min (1-mm margin) and R0wide (> 1-mm margin).</p> <p><strong>Results: </strong> A total of 340 resection areas in 136 patients were analyzed (70 R0min, 143 R0wide, 31 R1vasc, 96 R1par). HGP was desmoplastic in 26 cases, pushing in 221, and replacement in 93. Thirty-six local recurrences occurred (11%, median follow-up 21 months): 1 after R0wide, 4 after R0min, 3 after R1vasc, and 28 after R1par resection. In R1par group, local recurrence rate was high independently of HGP (29%). In R1vasc and R0min groups, local recurrence risk was higher in the replacement group (R1vasc: 29% vs. 4% if pushing/desmoplastic; R0min: 11% vs. 4%). In R0wide group, local recurrence risk was low for all HGP ( < 1%). Independent predictors of local recurrence were replacement HGP (odds ratio = 1.654, P = 0.036), and R1par resection (odds ratio = 57.209, P < 0.001 vs. R0).</p> <p><strong>Conclusions: </strong> Replacement HGP is associated with an increased risk of local recurrence. In these patients, a wide surgical margin should be pursued, because R1vasc and R0min resections could be insufficient. R1par resection is inadequate, independently of the HGP</p> <p><br> </p>
An in vitro and ex vivo model of biomimetic regenerative devices to treat bone metastases and soft tissue tumors: BIOBOS PROJECT (Moh GR-2016-02364704)
<p>Biobos is a project funded by Italian MoH <strong>GR-2016-02364704 Other Italian Institutes involved: Istituto Ortopedico Rizzoli, Bologna CNR, Faenza</strong></p> <p>The hypothesis of BIOBOS is that the development of nanostructured biomimetic materials medicated with a chemotherapeutic drug and with one used for tissue regeneration will be an innovative strategy to be integrated with the current multidisciplinary treatment options on patients with bone metastases from breast cancer and on patients with soft tissue sarcomas. Three types of medicated materials have been developed: i) porous scaffolds and ii) self-regulating biomimetic pastes (bone cements) with anti-osteoporotic functions to be applied in the future in patients with bone metastases; both materials were functionalized with the standard chemotherapy doxorubicin, and an anti-RANKL antibody, which by blocking osteoclast differentiation, helps tissue regeneration in lytic-type metastases; iii) polymeric nanofibrous tissue-nonwoven mesh functionalized with the chemotherapeutic epirubicin and the anti-inflammatory diclofenac, used to evaluate its regenerative potential. After the synthesis and characterization of the materials, the functionalization of the drugs at optimal concentrations for local release was optimized for the bone cements and for the meshes, so as to have the release of the chemotherapeutic and subsequently of the regenerative drug. Meanwhile, on non-medicated materials, the monoculture and coculture conditions of tumor cells (of breast cancer for bone metastasis applications; an epithelial sarcoma cell line for application on sarcomas) and stromal cells (osteoclasts and osteoblasts for applications on bone metastases, a cell line of healthy murine fibroblasts for application on sarcomas. For both pathologies, after approval by the Local Ethics Committee, biological samples were collected to test the ex vivo efficacy of the materials medicated on explants or primary cultures.</p>
Dataset related to article "Multimodal Treatments for Brain Metastases from Renal Cell Carcinoma: Results of a Multicentric Retrospective Study "
<p>This record contains raw data related to article "Multimodal Treatments for Brain Metastases from Renal Cell Carcinoma: Results of a Multicentric Retrospective Study"</p><p>Abstract</p><p>The aim of this study was to evaluate the clinical outcomes of a large series of brain metastatic renal cell carcinoma (BMRCC) patients treated in three Italian centers.</p><p><strong>Methods: </strong>A total of 120 BMRCC patients with a total of 176 lesions treated were evaluated. Patients received surgery plus postoperative HSRS, single-fraction SRS, or hypofractionated SRS (HSRS). Local control (LC), brain distant failure (BDF), overall survival (OS), toxicities, and prognostic factors were assessed.</p><p><strong>Results: </strong>The median follow-up time was 77 months (range 16-235 months). Surgery plus HSRS was performed in 23 (19.2%) cases, along with SRS in 82 (68.3%) and HSRS in 15 (12.5%). Seventy-seven (64.2%) patients received systemic therapy. The main total dose and fractionation used were 20-24 Gy in single fraction or 32-30 Gy in 4-5 daily fractions. Median LC time and 6 month and 1, 2 and 3 year LC rates were nr, 100%, 95.7% ± 1.8%, 93.4% ± 2.4%, and 93.4% ± 2.4%. Median BDF time and 6 month and 1, 2 and 3 year BDF rates were n.r., 11.9% ± 3.1%, 25.1% ± 4.5%, 38.7% ± 5.5%, and 44.4% ± 6.3%, respectively. Median OS time and 6 month and 1, 2 and 3 year OS rates were 16 months (95% CI: 12-22), 80% ± 3.6%, 58.3% ± 4.5%, 30.9% ± 4.3%, and 16.9% ± 3.6, respectively. No severe neurological toxicities occurred. Patients with a favorable/intermediate IMDC score, a higher RCC-GPA score, an early occurrence of BMs from primary diagnosis, absence of EC metastases, and a combined local treatment (surgery plus adjuvant HSRS) had a better outcome.</p><p><strong>Conclusions: </strong>SRS/HSRS is proven to be an effective local treatment for BMRCC. A careful evaluation of prognostic factors is a valid step to manage the optimal therapeutic strategy for BMRCC patients.</p>
Dataset related to article "Radiosurgery of limited brain metastases from primary solid tumor: results of the randomized phase III trial (NCT02355613) comparing treatments executed with a specialized or a C-arm linac-based platform"
<p>This record contains raw data related to article "Radiosurgery of limited brain metastases from primary solid tumor: results of the randomized phase III trial (NCT02355613) comparing treatments executed with a specialized or a C-arm linac-based platform"</p><p>Abstract</p><p>Background: Comparative prospective data regarding different radiosurgery (SRS) modalities for treating brain metastases (BMs) from solid tumors are not available. To investigate with a single institute phase III randomized trial whether SRS executed with linac (Arm-B) is superior to a dedicated multi-source gamma-ray stereotactic platform (Arm-A).</p><p>Methods: Adults patients with 1-4 BMs from solid tumors up to 30 mm in maximum diameter were randomly assigned to arms A and B. The primary endpoint was cumulative incidence of symptomatic (grade 2-3) radionecrosis (CIRN). Secondary endpoints were local progression cumulative incidence (CILP), distant brain failure, disease-free survival (DFS), and overall survival (OS).</p><p>Results: A total of 251 patients were randomly assigned to Arm-A (121) or Arm-B (130). The 1-year RN cumulative incidence was 6.7% in whole cohort, 3.8% (95% CI 1.9-7.4%) in Arm-B, and 9.3% (95% CI 6.2-13.8%) in the Arm-A (p = 0.43). CIRN was influenced by target volume irradiated only for the Arm-A (p << 0.001; HR 1.36 [95% CI 1.25-1.48]). Symptomatic RN occurred in 56 cases at a median time of 10.3 months (range 1.15-54.8 months), 27 in the Arm-B at a median time of 15.9 months (range 4.9-54.8 months), and 29 in the Arm-A at a median time of 6.9 months (1.2-32.3 months), without statistically significant differences between the two arms. No statistically significant differences were recorded between the two arms in CILP, BDF, DFS or OS. The mean beam-on time to deliver SRS was 49.0 ± 36.2 min in Arm-A, and 3.1 ± 1.6 min in Arm-B.</p><p>Conclusions: Given the technical differences between the treatment platforms investigated in this single-institution study, linac-based SRS (Arm-B) did not lead to significantly lower grade 2-3 RN rates versus the multi-source gamma-ray system (Arm-A) in a population of patients with limited brain metastases of small volume. No significant difference in local control was observed between both arms. For Arm-B, the treatment delivery time was significantly lower than for Arm-A.</p><p> </p><p>Trial registration: ClinicalTrials.gov Identifier NCT02355613.</p><p> </p>
Discordant molecular subtype classification of muscle-invasive bladder cancer and matched lymph-node metastases occurs preferentially in the Basal/Squamous-like subtype.
GEO Series GSE101723. Homo sapiens. 28 samples. Type: Expression profiling by array.
RNA seq analysis of primary tumors and metastases from the NPK (Nkx3.1CreERT2/+; Ptenflox/flox; KrasLSL-G12D/+; R26R-CAG-LSL-EYFP/+) prostate cancer mouse model
GEO Series GSE143812. Mus musculus. 62 samples. Type: Expression profiling by high throughput sequencing.
Lack of genetic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastases
GEO Series GSE38888. Homo sapiens. 42 samples. Type: Genome variation profiling by genome tiling array.
TBCRC 018: Phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
GEO Series GSE51280. Homo sapiens. 24 samples. Type: Expression profiling by array.
The metastatic microenvironment. Brain-derived soluble factors alter the malignancy phenotype of cutaneous and brain- metastasizing melanoma cells
GEO Series GSE34970. Homo sapiens. 4 samples. Type: Expression profiling by array.
Affymetrix HG-U133A 2.0 Expression data from 6 human cell lines derived from metastasized melanoma
GEO Series GSE62682. Homo sapiens. 6 samples. Type: Expression profiling by array.
Dataset related to article "Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study"
<p>This record contains raw data related to article "Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study"</p><p>Abstract</p><p><strong>Purpose: </strong>The lung is the most frequent site of metastasis in patients with sarcoma. Pulmonary metastasectomy is the most common treatment performed. Stereotactic body radiation therapy (SBRT) has proven to be a potential alternative to resection. This prospective phase 2 study aimed to assess the role of SBRT for patients with lung metastases.</p><p><strong>Methods and materials: </strong>Adult patients with up to 4 lung metastases (LMs) ≤5 cm in diameter and unsuitable for surgery were included. Dose prescription was based on site and size: 30 Gy/1 fraction for peripheral lesions ≤10 mm, 60 Gy/3 fractions for peripheral lesions 11 to 20 mm, 48 Gy/4 fractions for peripheral lesions >20 mm, and 60 Gy/8 fractions for central lesions. The primary endpoint was the proportion of treated lesions free from progression at 12 months. Secondary endpoints were disease-free survival (DFS), overall survival (OS), and toxicity.</p><p><strong>Results: </strong>Between March 2015 and December 2020, 44 patients with a total of 71 LMs were enrolled. Twelve-month local control was 98.5% ± 1.4%, reaching the primary aim; the median DFS time was 12 months (95% CI, 8-16 months), and the 1-, 2-, 3-, 4-, and 5-year PFS rates were 50% ± 7.5%, 19.5% ± 6.6%, 11.7% ± 5.8%, 11.7% ± 5.8%, and 11.7% ± 5.8%, respectively. The median OS time was 49 months (95% CI, 24-49 months), and the 1-, 2-, 3-, 4-, and 5-year OS rates were 88.6% ± 4.7%, 66.7 ± 7.6%, 56.8% ± 8.4%, 53.0% ± 8.6%, and 48.2% ± 9.1%, respectively. Prognostic factors recorded as significantly affecting survival were age, grade of primary sarcoma, interval time from diagnosis to occurrence of LMs, and number of LMs. No severe pulmonary toxicity (grade 3-4) occurred.</p><p><strong>Conclusions: </strong>The study found a local control of LMs in almost all patients treated, with negligible toxicity. Survival was also highly satisfactory. Well-designed randomized trials comparing surgery with SBRT for patients with metastatic lung sarcoma are needed to confirm these preliminary data</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.